Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study.

ABSTRACT:

Background

Approximately half of the patients with advanced pancreatic ductal adenocarcinoma (PDAC) receive subsequent lines of chemotherapy. Recently, the liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) regimen is recommended as subsequent lines of chemotherapy. However, little is known about the predictive factors for the nal-IRI + 5-FU/LV regimen, especially in patients with previous irinotecan (IRI) exposure.

Objectives

We investigated the predictive factors associated with nal-IRI + 5-FU/LV treatment in patients with PDAC.

Design

Multicenter, retrospective cohort study.

Methods

This study included patients with advanced PDAC who received the nal-IRI + 5-FU/LV regimen for palliative purposes.

Results

Overall, 268 patients were

SUBMITTER: Keum J 

PROVIDER: S-EPMC11425736 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature